Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Long-Term Investments (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Long-Term Investments data on record, last reported at $11.5 million in Q3 2025.

  • For Q3 2025, Long-Term Investments fell 24.08% year-over-year to $11.5 million; the TTM value through Sep 2025 reached $11.5 million, down 24.08%, while the annual FY2024 figure was $12.5 million, 22.22% down from the prior year.
  • Long-Term Investments reached $11.5 million in Q3 2025 per CRVS's latest filing, down from $11.8 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $33.4 million in Q1 2022 and bottomed at $11.5 million in Q3 2025.
  • Average Long-Term Investments over 4 years is $18.5 million, with a median of $16.1 million recorded in 2023.
  • Peak YoY movement for Long-Term Investments: crashed 40.3% in 2023, then dropped 11.04% in 2024.
  • A 4-year view of Long-Term Investments shows it stood at $21.9 million in 2022, then decreased by 26.3% to $16.1 million in 2023, then dropped by 22.22% to $12.5 million in 2024, then fell by 8.05% to $11.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $11.5 million in Q3 2025, $11.8 million in Q2 2025, and $12.1 million in Q1 2025.